Hedge Fund Database
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
The curated database of hedge funds that publish investor letters. Research by geography, strategy, and schools of thought.
| # | Fund | Strategy | Style | Geography | AUM | Latest Letter |
|---|---|---|---|---|---|---|
As of Oct 15, 2026
Dodge & Cox Stock Fund (Class I) returned 1.30% net of fees in the third quarter of 2026, trailing the S&P 500 Index's 2.30% gain and the Russell 1000 Value Index's 2.61% advance. Year to date, the Fund has returned 5.16% net of fees, lagging the S&P 500 and Russell 1000 Value by 7.6 and 14.1 percentage points, respectively. Relative performance during the quarter was dampened by an underweight posture in Information Technology alongside stock selection in Health Care, though underweight allocations to Consumer Discretionary and Utilities partially mitigated benchmark underperformance. The macroeconomic landscape was shaped by persistent inflation, durable U.S. economic growth, and substantial debt financing for artificial intelligence infrastructure, which prompted the Federal Reserve to raise short-term rates by 25 basis points. Long-term interest rates expanded concurrently, driving 10-year Treasury yields to their highest levels since 2007. Market concentration remained historically elevated, with the five largest constituents representing 31% of S&P 500 capitalization, despite a sharp quarterly pullback across semiconductor shares driven by questions over artificial intelligence spending durability. Capitalizing on artificial intelligence sentiment dislocations, management initiated new positions in franchises where disruption risks appear overstated, such as Roper Technologies, while scaling exposure to long-term beneficiaries including Microsoft and Amazon. Within Health Care, the Fund rotated capital away from pharmaceuticals into Life Sciences Tools and Medical Equipment, establishing new holdings in Boston Scientific and Danaher following multi-year destocking cycles. The aggregate portfolio trades at 13.4 times forward earnings, reflecting a substantial discount to the S&P 500.
A bottom-up, value-driven investment approach focused on identifying fundamentally sound franchises trading at substantial discounts over a long-term three- to five-year horizon.
Management remains anchored in long-term fundamental analysis over a three- to five-year investment horizon, encouraging investors to look past short-term volatility stemming from narrow market leadership. The portfolio trades at an attractive valuation of 13.4 times forward earnings, representing a meaningful discount to both the S&P 500 at 19.2 times and the Russell 1000 Value at 17.2 times, with broad thematic diversification designed to navigate an uncertain macro regime.
Moderate Conviction Bullish
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon
Top Conviction Themes
Key Catalysts
Every insight in this database connects to the original source. Read the actual thesis, see the actual concerns, and make your own call.
Buyside Digest has no business relationship, partnership, agency, sponsorship, endorsement, or affiliation with Dodge & Cox Stock Fund or any other manager whose content appears on the Service, except where expressly stated. We do not receive Manager Content directly from managers in most cases; content is collected from publicly available sources. Managers have not necessarily reviewed, approved, authorized, or endorsed our display of their content, our editorial commentary, our metadata extraction, or our classifications. Use of a manager’s name is for accurate attribution and identification purposes only, under principles of nominative fair use.
Buyside Digest does not independently verify the regulatory status, registrations, licensing, qualifications, credentials, or professional standing of managers whose content appears on the Service. We do not represent that managers are properly registered with applicable regulatory bodies, that their content complies with applicable securities laws, or that their performance representations are accurate. Inclusion of a manager in our database is based on the publicly available nature of their content, not on our verification of their regulatory status or content compliance. Users are responsible for conducting their own due diligence on any manager.
Performance data, returns, assets under management (“AUM”), and similar figures displayed on this page are sourced from publicly available manager communications (including investor letters), public filings, or other third-party sources. Buyside Digest does not independently verify performance figures, calculate returns, or audit manager-reported data. Such figures: May be selectively reported by the manager; May use non-standard calculation methodologies; May not reflect fees, expenses, taxes, or other costs; May be inconsistent across reporting periods; May be outdated. Past performance is not indicative of future results. Performance figures should not be relied upon for investment decisions without independent verification. Users should request audited performance data directly from the manager and conduct their own due diligence.